The work of Lebrecht and her coworkers [11] in the 2004 show the analysis of serum MCP-1 level in patients with invasive breast cancer, ductal carcinoma in situ, benign breast lesions, and healthy women. Here, CCL2 is linked to ductal breast carcinoma in situ.